Oncology News | pharmaphorum

News

Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia

MSD starts second phase 3 of Imago drug for blood cancers

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

J&J's Balversa is first pan-FGFR bladder cancer drug in EU

Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic alterations after one line of prior

News

Specialists on radioligand therapy production line

Healthineers offers €200m for Novartis radiodiagnostics unit

Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis' Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imag

News

Blood smear from a person with myelodysplastic syndrome

ICER says Geron's just-approved Rytelo is too pricey

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institu

News

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category

MSD starts second phase 3 of Imago drug for blood cancers

After FDA no, Regeneron gets yes from EU on odronextamab

J&J's Balversa is first pan-FGFR bladder cancer drug in EU

Healthineers offers €200m for Novartis radiodiagnostics unit

ICER says Geron's just-approved Rytelo is too pricey

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks